Pfizer Appeals Federal Ruling, Seeks Reinstatement of $107.5 Million Verdict Against AstraZeneca

Pfizer has challenged a federal judge’s decision to overturn a Delaware jury’s verdict, which had previously determined that AstraZeneca owed $107.5 million for patent infringement related to two cancer drugs. In an appeal to the Federal Circuit, a Pfizer division argued that the judge had made an error in dismissing the jury’s findings. The case revolves around the contentious interpretation and application of patent law, a subject that continues to occupy the courts and legal experts. Detailed information about the developments in this case can be found through Law360.